For mCRPC patients, drug resistance to 2nd-generation AR signaling inhibitors (ARSi), such as abiraterone and enzalutamide is essentially universal in tumor cells that often come with significantly elevated expression of truncated AR splice variant-7 (AR-V7) [47]. The gene discussed is AR; the disease is neoplasm.